Phlebotomy for Hemochromatosis: Schedule and Side Effects

Phlebotomy, the controlled removal of blood, remains the primary treatment for hereditary hemochromatosis and has been for decades. Each session pulls roughly 450 to 500 mL of blood from a vein, and because red blood cells are packed with iron, the body is forced to tap its overloaded iron stores to make new ones. The approach is simple, effective, and when started early enough, can normalize life expectancy. But the experience of living with regular blood draws over a lifetime is more complicated than the treatment sounds on paper.

Why Blood Removal Works for Iron Overload

Hemochromatosis is fundamentally a problem of too much iron getting absorbed from food. In the most common form (HFE-related, tied to the C282Y mutation), the liver underproduces a hormone called hepcidin, which normally acts as a gatekeeper controlling how much dietary iron enters the bloodstream.¹ Without enough hepcidin, iron absorption runs higher than it should, and the excess accumulates in organs like the liver, heart, pancreas, and joints.²

The body has no natural mechanism for excreting large amounts of iron. You lose small amounts through skin shedding, sweat, and minor bleeding, but nothing close to what hemochromatosis patients absorb. Phlebotomy works by exploiting the biology of red blood cell production. When you remove a unit of blood, the bone marrow ramps up to replace the lost red cells, and each new red cell requires iron. That iron gets pulled from tissue stores, particularly the liver. Over repeated sessions, iron that had been accumulating in organs for years is gradually drawn out and consumed in the process of making new blood.

The drawdown is not perfectly smooth. After an initial decline in ferritin levels (the standard blood marker used to track iron stores), there can be a temporary plateau, likely reflecting iron being mobilized from various tissues into the bloodstream before it gets used up.³ This is normal and does not mean the treatment has stopped working.

What a Treatment Schedule Looks Like

Treatment typically unfolds in two phases. During the induction phase, the goal is to bring ferritin levels down to target as quickly as is safely tolerable. This usually means a phlebotomy session every one to two weeks, each removing about 450 to 500 mL of blood. For someone diagnosed with heavily loaded iron stores, the induction phase can take many months or even more than a year, depending on how high ferritin was at diagnosis.

European guidelines recommend driving ferritin below 50 μg/L during induction and keeping it below 100 μg/L during the ongoing maintenance phase.⁴ Once ferritin reaches target, sessions become less frequent, typically every two to four months for life. The exact interval varies from person to person. Some people reaccumulate iron faster than others, and your doctor adjusts the schedule based on periodic blood tests tracking ferritin and transferrin saturation.

Each session itself is straightforward. A needle goes into a vein, blood is drawn into a collection bag over 15 to 30 minutes, and you rest briefly before leaving. It is essentially the same procedure as donating blood, and in many cases, the same equipment is used.

What Phlebotomy Can and Cannot Reverse

One of the most encouraging findings in hemochromatosis treatment is that liver fibrosis, including advanced scarring, can partially reverse with iron depletion. A study of 36 patients with genetic hemochromatosis who had significant liver fibrosis or cirrhosis at the start of treatment found striking improvements after sustained phlebotomy. Among patients who initially had advanced fibrosis (just short of cirrhosis), about 69% showed regression of at least two fibrosis stages. Even among patients who already had full cirrhosis, 35% achieved that degree of improvement.⁵ On a cellular level, phlebotomy reduces the activation of the liver cells responsible for producing scar tissue.⁶

Heart problems caused by iron deposits can also improve. In case reports of patients with heart failure attributed to hemochromatosis, sustained phlebotomy has led to normalization of heart function.⁷ Cardiac iron overload tends to be more reversible than damage to some other organs, likely because heart muscle cells can release stored iron when the body demands it for new red blood cells.

Diabetes and joint disease are the stubborn exceptions. Phlebotomy does not reliably improve blood sugar control in patients with hemochromatosis-related diabetes, probably because the pancreatic beta cells that produce insulin have already been permanently damaged by the time iron overload is severe enough to cause diabetes.⁸ These patients typically need standard diabetes management on top of their phlebotomy schedule.⁹

Joint disease is perhaps the most frustrating complication. Joint pain in hemochromatosis often persists or even worsens despite successful iron depletion, and it is one of the top complaints that erode quality of life in treated patients. The reasons are not entirely clear, but iron deposits in joint cartilage seem to trigger a destructive process that continues even after iron levels normalize.

Side Effects and Patient Experience

Phlebotomy is generally safe, but “safe” and “pleasant” are different things. A survey of hemochromatosis patients found that while 87% considered the treatment worthwhile, more than half of those in the induction phase reported side effects always or most of the time after sessions, and about 37% of maintenance patients said the same. Given the option, 16% said they would probably or definitely decline phlebotomy if alternatives existed.¹⁰ Common complaints include fatigue, lightheadedness, and feeling drained for a day or two after a session.

There is also a real risk of overcorrection. A case series documented 13 hemochromatosis patients who developed outright iron deficiency during maintenance phlebotomy. Their transferrin saturation dropped to about 10%, ferritin fell to around 8 ng/mL, and 11 of the 13 became anemic. On average, the iron deficiency had persisted for about two years before anyone caught it.¹¹ The lesson here is that hemochromatosis treatment needs regular monitoring, not just a fixed schedule. Ferritin and hemoglobin checks before each session help prevent the pendulum from swinging too far in the other direction.

Long-term venous access can become a practical headache as well. Years of repeated needle punctures at the same sites can lead to scarring and hardening of veins, making future draws more difficult. Careful vein rotation and site preservation become increasingly important the longer treatment continues.

Quality of Life Beyond Iron Numbers

Getting ferritin into the target range does not automatically mean feeling well. A scoping review identified fatigue, joint pain, sexual dysfunction, reduced vitality, and diminished psychological wellbeing as the top factors linked to impaired quality of life in hemochromatosis patients.¹² Many of these symptoms persist during maintenance therapy.

A prospective study of 259 patients during maintenance found that the median fatigue score was 3 out of 10 and that two-thirds reported ongoing joint pain. Interestingly, patients whose transferrin saturation dropped below 20% actually reported worse joint pain, suggesting that aggressive iron depletion does not help and might even aggravate musculoskeletal symptoms.¹³ Age was also a strong predictor of both fatigue and reduced physical function. The disease’s impact on daily life is real, and it is something patients and their doctors increasingly recognize needs attention beyond just the ferritin number on a lab slip.

Can You Donate the Blood?

This is one of the most common questions from patients, and the answer depends on where you live. Policies vary globally, and for years many blood centers, including numerous facilities in the United States, refused to accept blood drawn during therapeutic phlebotomy for hemochromatosis. The concern was theoretical rather than evidence-based. A review examining biological and clinical data on infectious risk found no convincing evidence to exclude hemochromatosis patients from the donor pool, concluding that their blood is safe for transfusion recipients.¹⁴

A prospective study that enrolled hemochromatosis patients as voluntary blood donors found they could safely and meaningfully augment the blood supply. The authors also noted a practical benefit: when phlebotomy is provided through a blood donation center without cost barriers or worries about donation suitability, patients have better access to care and less incentive to hide health information during screening.¹⁵ In some countries, such as Sweden and Australia, hemochromatosis patients have been donating blood for years. The trend is moving toward broader acceptance, but policies change slowly, and you should check with your local blood center.

Alternatives to Standard Phlebotomy

For patients who dislike or struggle with frequent sessions, erythrocytapheresis is the main alternative. Instead of drawing whole blood, a machine selectively removes red blood cells (the iron-rich component) and returns the plasma and other blood components. Because it extracts more red cells per session, the intervals between treatments are longer.

A randomized crossover trial comparing the two methods during maintenance found that patients needed an average of 1.9 erythrocytapheresis sessions per year versus 3.3 standard phlebotomies, and the time between treatments was about 2.3 times longer with erythrocytapheresis. Eighty percent of patients preferred the apheresis method. The tradeoff was cost: the average annual expense was roughly double for erythrocytapheresis.¹⁶ Another study found that while erythrocytapheresis produced a faster initial drop in ferritin and required fewer total procedures, the time to reach the target ferritin level was the same as with standard phlebotomy, and material costs were roughly three times higher.¹⁷

Iron chelation drugs, which bind iron in the body so it can be excreted, are the standard treatment for iron overload in patients with severe anemias who cannot tolerate blood removal. These drugs have been discussed as potential alternatives to phlebotomy in hemochromatosis, though they carry their own side effects and costs and are not the first-line approach for people who can tolerate phlebotomy.¹⁸ They remain most relevant for the subset of patients with poor venous access or medical reasons that make blood removal impractical.

Dietary Measures as a Complement

Diet cannot replace phlebotomy, but it can reduce the rate at which iron reaccumulates between sessions. Because hemochromatosis involves enhanced intestinal iron absorption due to low hepcidin, dietary changes that lower iron intake or reduce how well iron is absorbed from food can modestly slow the buildup.¹⁹

Practical steps include drinking tea or coffee with meals (the tannins and polyphenols inhibit iron absorption), avoiding vitamin C supplements around mealtimes (vitamin C enhances iron uptake), limiting red meat and organ meats (which are high in easily absorbed heme iron), and favoring whole grains and legumes (which contain compounds that reduce iron bioavailability). None of these measures alone will move your ferritin much, but in aggregate they may lengthen the interval between phlebotomy sessions. For patients who find the treatment schedule burdensome, even an extra few weeks between draws is meaningful.

Long-Term Prognosis with Treatment

The survival data for treated hemochromatosis is both reassuring and sobering, depending on when the diagnosis happens. Patients diagnosed before they develop cirrhosis or diabetes and treated with phlebotomy have a life expectancy identical to the general population.²⁰ That is a powerful argument for early screening and treatment.

For those diagnosed later, after cirrhosis has already set in, the picture is different. An earlier landmark study found that life expectancy was reduced in patients with cirrhosis compared to those without it, and separately reduced in patients with diabetes. Patients who could not be fully depleted of iron within the first 18 months of treatment also had worse outcomes. Even when complete iron depletion was achieved, cirrhotic patients remained at elevated risk for liver cancer.²¹ This is why ongoing liver surveillance, usually with ultrasound, remains standard for anyone who had cirrhosis at diagnosis, regardless of how well iron levels respond to treatment.

Why Disease Severity Varies So Much

Not everyone with the same hemochromatosis genotype needs the same intensity of treatment, and researchers are getting closer to understanding why. A UK Biobank study of male C282Y homozygotes found that a polygenic score for transferrin saturation (essentially a measure of how many other iron-related gene variants a person carries on top of C282Y) meaningfully influenced outcomes. Men in the highest-risk genetic quintile had a cumulative incidence of hemochromatosis-related clinical problems of about 65% by age 80, compared with roughly 52% in the lowest-risk quintile. The higher-risk group also showed increased odds of liver fibrosis, cirrhosis, and joint replacement surgeries.²²

In women, the same genetic score predicted hemochromatosis diagnosis but did not significantly predict liver disease, likely because menstrual iron losses provide a protective buffer during premenopausal years. This partly explains why women with the same C282Y genotype tend to present later and with less severe iron loading than men.

Rarer forms of hemochromatosis, such as juvenile hemochromatosis caused by mutations in the HJV gene, tend to present much earlier in life and with more aggressive iron loading. Phlebotomy is still the treatment, but the schedule may be more intensive. A case report of a young patient with juvenile hemochromatosis described weekly phlebotomy during induction, with ferritin dropping to target after six sessions, followed by maintenance of two to five sessions per year.²³ The principles are the same across subtypes: remove iron, monitor levels, adjust frequency.

A Treatment Older Than Modern Medicine

There is something remarkable about the fact that the standard treatment for a genetic disease discovered in the molecular era is, at its core, the ancient practice of bloodletting. Therapeutic venesection has roots stretching back thousands of years, long before anyone understood iron metabolism or gene mutations.²⁴ For most of its history, bloodletting was applied indiscriminately and often harmfully. Hemochromatosis turns out to be one of the rare conditions where the ancient instinct was right, albeit for entirely different reasons than medieval practitioners imagined. Despite advances in chelation drugs and apheresis technology, simple blood removal remains the first-line treatment, and there is no serious movement to replace it. The procedure works, it is inexpensive, and when started early, it prevents nearly all of the disease’s serious consequences. What has changed is the precision: we now know whom to treat, when to start, what to target, and when to stop.